Answers are grounded in this paper and cite their sources.
AIM: Endogenous cortisol, a stress biomarker, is used as a cytochrome P450 3A-dependent biomarker for human phenotyping. Because adrenal hypofunction is characterized by low endogenous plasma cortisol levels, exogenous cortisol is therapeutically administered orally in two or three divided daily doses. Simple pharmacokinetic models were established for cortisol monitoring following oral administration. METHODS: One set of model input parameters was based on reported plasma cortisol values in two male Japanese volunteers (designated A and B) orally administered deuterium-labelled cortisol. Simple physiologically based pharmacokinetic (PBPK) models were also extrapolated from humanized-liver mice data and used to predict human steady-state plasma concentrations of cortisol and its 6β-hydroxylated metabolite. RESULTS: Four groups of humanized-liver mice were used, each with a different human donor. The cortisol clearance values varied by a factor of two across the four groups. This variability was reflected in the in silico clearance values generated as input parameters for PBPK models. Virtual human area-under-the-curve values after oral cortisol (18 mg/day total for 1 week) administered as divided doses once, twice, or thrice daily were used to calculate the mean cortisol and 6β-hydroxycortisol concentrations. For Human A, the mean cortisol level was double that of Human B under the present simulations. CONCLUSIONS: When using 6β-hydroxycortisol as an endogenous biomarker for clinical treatment with exogenous agents, the dosage and timing of oral cortisol should be determined considering individual variations, such as body weight and the twofold variability in baseline normal metabolic enzyme activity.
No takes yet. Share an insight, caveat, or question.
Yamazaki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: